Galmarini CM - Search Results

1

Influence of p53 and p21(WAF1) expression on sensitivity of cancer cells to cladribine.

Galmarini CM, Voorzanger N, Falette N, Jordheim L, Cros E, Puisieux A, Dumontet C. Galmarini CM, et al. Biochem Pharmacol. 2003 Jan 1;65(1):121-9. doi: 10.1016/s0006-2952(02)01448-x. Biochem Pharmacol. 2003. PMID: 12473386

2

Expression of a non-functional p53 affects the sensitivity of cancer cells to gemcitabine.

Galmarini CM, Clarke ML, Falette N, Puisieux A, Mackey JR, Dumontet C. Galmarini CM, et al. Int J Cancer. 2002 Feb 1;97(4):439-45. doi: 10.1002/ijc.1628. Int J Cancer. 2002. PMID: 11802204

3

Resistance to gemcitabine in a human follicular lymphoma cell line is due to partial deletion of the deoxycytidine kinase gene.

Galmarini CM, Clarke ML, Jordheim L, Santos CL, Cros E, Mackey JR, Dumontet C. Galmarini CM, et al. BMC Pharmacol. 2004 May 24;4:8. doi: 10.1186/1471-2210-4-8. BMC Pharmacol. 2004. PMID: 15157282 Free PMC article.

4

A p21/WAF1 mutation favors the appearance of drug resistance to paclitaxel in human noncancerous epithelial mammary cells.

Galmarini CM, Bouchet BP, Audoynaud C, Lamblot C, Falette N, Bertholon J, Wang Q, Beghin A, Dumontet C, Puisieux A. Galmarini CM, et al. Int J Cancer. 2006 Jul 1;119(1):60-6. doi: 10.1002/ijc.21770. Int J Cancer. 2006. PMID: 16432835

5

Inactivation of wild-type p53 by a dominant negative mutant renders MCF-7 cells resistant to tubulin-binding agent cytotoxicity.

Galmarini CM, Falette N, Tabone E, Levrat C, Britten R, Voorzanger-Rousselot N, Roesch-Gateau O, Vanier-Viornery A, Puisieux A, Dumontet C. Galmarini CM, et al. Br J Cancer. 2001 Sep 14;85(6):902-8. doi: 10.1054/bjoc.2001.2017. Br J Cancer. 2001. PMID: 11556844 Free PMC article.

6

Drug resistance associated with loss of p53 involves extensive alterations in microtubule composition and dynamics.

Galmarini CM, Kamath K, Vanier-Viornery A, Hervieu V, Peiller E, Falette N, Puisieux A, Ann Jordan M, Dumontet C. Galmarini CM, et al. Br J Cancer. 2003 Jun 2;88(11):1793-9. doi: 10.1038/sj.bjc.6600960. Br J Cancer. 2003. PMID: 12771997 Free PMC article.

7

Potential mechanisms of resistance to cytarabine in AML patients.

Galmarini CM, Thomas X, Calvo F, Rousselot P, El Jafaari A, Cros E, Dumontet C. Galmarini CM, et al. Leuk Res. 2002 Jul;26(7):621-9. doi: 10.1016/s0145-2126(01)00184-9. Leuk Res. 2002. PMID: 12008078

8

In vivo mechanisms of resistance to cytarabine in acute myeloid leukaemia.

Galmarini CM, Thomas X, Calvo F, Rousselot P, Rabilloud M, El Jaffari A, Cros E, Dumontet C. Galmarini CM, et al. Br J Haematol. 2002 Jun;117(4):860-8. doi: 10.1046/j.1365-2141.2002.03538.x. Br J Haematol. 2002. PMID: 12060121 Free article.

9

Nucleoside analogues and nucleobases in cancer treatment.

Galmarini CM, Mackey JR, Dumontet C. Galmarini CM, et al. Lancet Oncol. 2002 Jul;3(7):415-24. doi: 10.1016/s1470-2045(02)00788-x. Lancet Oncol. 2002. PMID: 12142171 Review.

10

Role of IMP-selective 5'-nucleotidase (cN-II) in hematological malignancies.

Galmarini CM, Jordheim L, Dumontet C. Galmarini CM, et al. Leuk Lymphoma. 2003 Jul;44(7):1105-11. doi: 10.1080/1042819031000077142. Leuk Lymphoma. 2003. PMID: 12916861 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

129 results

Search Page

Filters